Researchers found that a newer member of the taxane family, cabazitaxel, has properties that could make it more effective for some prostate cancer patients.Researchers also found a genomic marker that could help physicians identify which patients might benefit most from cabazitaxel.
Treatment with Imbruvica (ibrutinib) was associated with an 88 percent overall response rate, with a median time on study of 23.3 months, in 16 patients with relapsed/refractory high-risk chronic lymphocytic leukemia in studies ranging from phase II to III.
Patients with indolent non-Hodgkin's lymphoma lived significantly longer without disease worsening or death when treated with Gazyva (obinutuzumab) plus bendamustine and followed by Gazyva alone, compared to bendamustine alone.
FDA approved Lenvima (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Lenvima was approved following a priority review.
The Pharmaceutical Research and Manufacturers of American Foundation launched a platform featuring resources on its competitive research grants and fellowships for young scientists.
THEODORE LAWRENCE was named the director of the University of Michigan Comprehensive Cancer Center. He succeeds Max Wicha, who founded the cancer center 27 years ago. Lawrence will continue to serve as chair of radiation oncology.
Five years into the making of CancerLinQ, the American Society of Clinical Oncology is poised to become the next big player in oncology bioinformatics.
The CancerLinQ database of electronic health records is going through testing at 15 practices, and will be made available for research projects later this year.
The Faculty Senate of MD Anderson Cancer Center asked UT System officials and the Board of Regents to “provide guidance” to the administration of the Houston-based center “in establishing milestones and timelines to implement measures to improve the morale of the faculty and the general health of the Institution.”
VARIAN MEDICAL SYSTEMS was selected to equip and service a new national proton therapy center in Aarhus, Denmark, with the Varian ProBeam proton therapy system.
